Robotic Cardiology Surgery Market Report 2026

The robotic cardiology surgery market size has grown rapidly in recent years. It will grow from $0.84 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, rising adoption of minimally invasive surgery techniques, expansion of robotic surgical installations in hospitals, growing surgeon familiarity with robotic platforms, improved clinical outcomes from robotic procedures.

The robotic cardiology surgery market size is expected to see rapid growth in the next few years. It will grow to $1.79 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to growing demand for advanced cardiac surgery solutions, rising investments in next-generation robotic platforms, expansion of robotic surgery training programs, increasing adoption of precision-guided cardiac interventions, ongoing innovation in robotic cardiology technologies. Major trends in the forecast period include increasing adoption of minimally invasive robotic procedures, growing integration of advanced imaging and navigation systems, expansion of surgeon training and simulation platforms, rising use of robotic-assisted cardiac interventions, enhanced focus on surgical precision and patient outcomes.

The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the robotic cardiology surgery market in the coming years. Cardiovascular disease (CVD) encompasses a group of disorders affecting the heart or blood vessels. The growing incidence of cardiovascular diseases is attributed to a combination of lifestyle choices, medical conditions, genetic factors, and environmental influences. Robotic cardiology surgery plays a vital role in enhancing the treatment of cardiovascular diseases by offering safer, more precise, and minimally invasive surgical solutions, ultimately improving patient outcomes and overall quality of care. For example, in January 2024, the American Heart Association, a US-based nonprofit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, representing a 4% rise from the previous year's rate of 224.4 per 100,000, following a 4.6% increase in 2023, marking the first consecutive rise in these rates in many years. Consequently, the growing prevalence of cardiovascular diseases is driving the demand for robotic cardiology surgery.

Major companies operating in the robotic cardiology surgery market are concentrating on creating innovative surgical solutions, such as assistive robotic devices (ARD), to improve precision in cardiac procedures, reduce invasiveness, and enhance patient outcomes through the integration of advanced technologies and real-time analytics. Assistive robotic devices (ARD) are robotic systems designed to aid individuals with disabilities or limited mobility by assisting with tasks such as movement, communication, or daily activities. These devices promote independence and enhance users’ quality of life. For example, in March 2024, CardioPrecision Ltd., a UK-based company specializing in robotic surgeries, introduced proof-of-concept robotic procedures for implanting an aortic valve replacement via a minimally invasive technique, following successful cadaver model trials. The robotic system increases precision and control during surgery, enabling surgeons to operate with higher accuracy and potentially improving overall procedural success. This minimally invasive method is noteworthy because it can result in less pain, decreased blood loss, and a lower infection risk, ultimately supporting faster patient recovery.

In June 2025, Medtronic, an Ireland-based provider of medical devices, surgical robotics, cardiac rhythm, and cardiovascular therapies, formed a partnership with IRCAD North America. Through this collaboration, Medtronic seeks to integrate its robotic surgery technologies, AI-enabled systems, and cardiac mapping/ablation platforms into IRCAD’s new training and innovation center, accelerating the adoption of robotic cardiology and minimally invasive cardiovascular procedures while advancing skill development. IRCAD North America is a U.S.-based organization focused on surgical education, research, and simulation for minimally invasive and robotic surgeries across cardiovascular, neurological, and other surgical specialties.

Major companies operating in the robotic cardiology surgery market are Abbott Laboratories, Medtronic PLC, Siemens Healthineers AG, Boston Scientific Corporation, Edwards Lifesciences Corporation, KARL STORZ SE & Co. KG, Renishaw PLC, CMR Surgical Limited, Corindus Vascular Robotics Inc., XACT Robotics Ltd., Titan Medical Inc., Asensus Surgical Inc., Intuitive Surgical Inc., Aurora Surgical Robotics Inc., Hansen Medical Inc., Stereotaxis Inc., SS Innovations International Inc., MicroPort Scientific Corporation, GE HealthCare Technologies Inc., Stryker Corporation.

North America was the largest region in the robotic cardiology surgery market in 2025. The regions covered in the robotic cardiology surgery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the robotic cardiology surgery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the robotic cardiology surgery market by increasing costs of imported robotic systems, precision instruments, imaging components, navigation software, and electronic subsystems used in cardiac procedures. Hospitals and research centers in North America and Europe are most affected due to reliance on imported high-value robotic platforms, while Asia-Pacific faces cost pressures on equipment procurement. These tariffs are increasing capital investment requirements and slowing system upgrades. However, they are also encouraging localized assembly, regional service partnerships, and domestic innovation in robotic surgical technologies.

The robotic cardiology surgery market research report is one of a series of new reports that provides robotic cardiology surgery market statistics, including robotic cardiology surgery industry global market size, regional shares, competitors with a robotic cardiology surgery market share, detailed robotic cardiology surgery market segments, market trends and opportunities, and any further data you may need to thrive in the robotic cardiology surgery industry. This robotic cardiology surgery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Robotic cardiology surgery is a minimally invasive surgical technique where surgeons use robotic systems to perform procedures on the heart. These robotic systems provide enhanced precision, flexibility, and control through small incisions, often resulting in less pain, reduced risk of infection, shorter hospital stays, and quicker recovery times for patients compared to traditional open-heart surgery.

The main product types and services of robotic cardiology surgery are robotic systems, instruments and accessories, maintenance services, and system services. Robotic systems are advanced, computer-assisted platforms that surgeons use to perform minimally invasive surgeries. The various equipment types include robot machines, navigation systems, planners, and simulators, among others. These are used by various end-users such as hospitals, and research centers.

The robotic cardiology surgery market consists of revenues earned by entities by providing services such as robotic hybrid procedures, robotic atrial septal defect (ASD) repair, and robotic tricuspid valve repair services. The market value includes the value of related goods sold by the service provider or included within the service offering. The robotic cardiology surgery market also includes sales of coronary artery bypass grafting systems, robotic surgical systems, and remote navigation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.